HilleVax (NASDAQ:HLVX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.
HilleVax (NASDAQ:HLVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, analysts expect HilleVax to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
HilleVax Price Performance
Shares of NASDAQ HLVX opened at $2.05 on Thursday. The stock's 50-day simple moving average is $2.01 and its two-hundred day simple moving average is $1.87. HilleVax has a twelve month low of $1.34 and a twelve month high of $2.17. The firm has a market capitalization of $102.79 million, a P/E ratio of -0.95 and a beta of 0.77.
Institutional Inflows and Outflows
An institutional investor recently raised its position in HilleVax stock. Jane Street Group LLC grew its stake in HilleVax, Inc. (NASDAQ:HLVX - Free Report) by 26.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,563 shares of the company's stock after buying an additional 11,991 shares during the period. Jane Street Group LLC owned approximately 0.11% of HilleVax worth $82,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 86.42% of the company's stock.
About HilleVax
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
